Small enough to care and big enough to deliver

News

15.07.2019

Spraypattern

We now offer Spray Pattern Testing for Biocides and Pesticides acc. FEA 644 (European Aerosol Federation) under GLP.
This method is helpful for the rapid characterisation of aerosol sprays and will provide a guide to the size and distribution of droplets within a spray pattern.
It is a required parameter during storage stability testing for spray applications.

14.06.2019

Wir bieten Ihnen ab jetzt auch Schulungen zur Einführung in die Gute Laborpraxis (GLP) an.

Die nächsten Seminare finden am 03.07.2019 und 27.11.2019 in Kirrweiler statt.

Weitere Informationen finden Sie hier

01.04.2019

LAUS had a promising business trip to Israel

LAUS provides testing services for the international chemical industry as Physico-Chemical Properties, In vitro Toxicology, Mutagenicity, Genotoxicity, Ecotoxicology, Biodegradation, Environmental Fate and Analytical Chemistry.

 

18.01.2019

We will present our testing services in the area of in vitro toxicology and genotoxicity/mutagenicity at this year’s SOT 58th Annual Meeting and ToxExpo.

Meet us at booth #4226.

 

ToxExpo

24.05.2018

Today LAUS received the newest Statement of GLP Compliance documenting that we passed the latest inspection by the authorities in November 2017. We are proud to say that we have been GLP compliant since 1999.

Statement of GLP Compliance

22.02.2018

05.10.2017

LAUS NEWS: All three in vitro skin sensitisation studies available under GLP

LAUS has established and fully validated the h-CLAT (human Cell Line Activation Test, OECD 442E) and is now able to perform all three studies available for in vitro skin sensitisation testing under GLP conditions (h-CLAT, DPRA, LuSens).

The h-CLAT (human Cell Line Activation Test) uses the human monocytic leukemia cell line THP-1. The up-regulation of the surface molecules CD54 and CD86 as markers of dendritic cell activation is measured by flow cytometry following cell staining with fluorochrome-tagged antibodies.

In vitro skin sensitisation testing can substitute the corresponding in vivo study, the LLNA (OECD 442B and 429), in many cases. Unlike the LLNA, which is a stand-alone study, in vitro skin sensitisation testing consists of an array of three studies, each of them targeting a key event in the Adverse Outcome Pathway (AOP) of skin sensitisation. A substance can be rated as a sensitiser with two consistent positive results.

     

Key event of AOP

 

Study

OECD

1

covalent interaction with skin proteins

DPRA

442C

2

keratinocyte response

LuSens

based on 442D

3

dendritic cell activation

h-CLAT

442E


The tests are interesting for clients from the following regulatory areas:

  • REACH (EC 1907/2006)
  • The CLP Regulation (EC 1272/2008)
  • The Biocidal Products Regulation (EC 528/2012)
  • The Plant Protection Products Regulation (EC 1107/2009)
  • The Cosmetics Regulation (EC 1223/2009)
  • And screening at non-regulatory stages of product development

 

Want to know more? Contact us at info@laus.group or http://www.laus.group